



21 December 2020

ASX ANNOUNCEMENT

NOTICE UNDER SECTION 708A OF THE CORPORATIONS ACT

This notice is given by Cynata Therapeutics Limited (the **Company**) pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company has today issued 6,930,460 fully paid ordinary shares at an issue price of \$0.70 per share (**Shares**) in accordance with the terms of a placement to professional and sophisticated investors announced to ASX on 11 December 2020 (**Placement**).

Pursuant to paragraph 708A(5)(e) of the Corporations Act, the Company gives notice that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of the Corporations Act; and
3. as at the date of this notice, there is no information that is “excluded information” (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company.

As announced to ASX on 18 December 2020, the balance of the shares to be issued under the Placement (representing approximately 14.5 million Shares) will be issued on Thursday, 24 December 2020.

Authorised by

A handwritten signature in blue ink, appearing to read "Ross Macdonald", written over a horizontal line.

Ross Macdonald
Managing Director & CEO

Contacts: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343,
ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, + 315.765.1462,
clacagnina@6degreespr.com